UNSPSC 51384626: Lonazolac calcium

This classification denotes a nonsteroidal antiinflammatory drug 2C17H12ClN2O2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H73O2AC36, chemically known as 1h-pyrazole-4-acetic acid, 3-(4-chlorophenyl)-1-phenyl-, calcium salt, but more generally known as lonazolac calcium, which bears US NIH Compound Identifier 156369. European Medicines Agency schedules Lonazolac calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02968MIG.

Most nations, for tariff and trade purposes, schedule lonazolac calcium under HS 29331990 and SITC 51571. As of Q4 2014, LONAZOLAC CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)N2CC(C(N2)C3CCC(CC3)CL)CC(=O)[O-].C1CCC(CC1)N2CC(C(N2)C3CCC(CC3)CL)CC(=O)[O-].[CA+2].

UNSPSC 51384626 Lonazolac calcium is a Commodity code that nominally identifies a specific nonsteroidal anti-inflammatory drug (NSAID) active pharmaceutical ingredient, but recent state and local procurement activity under this code shows minimal to no direct solicitation for lonazolac calcium itself. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products distributed through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations explicitly reference lonazolac calcium, indicating either a tagging mismatch in the source data or a collapse of pharmaceutical procurement categories within state and local systems that do not distinguish between specific active ingredients at the point of opportunity posting.

Activity under this code appears concentrated in cooperative purchasing vehicles and state health agencies rather than individual cities or counties. The Texas HHS Commission issued an RFI (posted April 3, 2026, response due April 3, 2026) to explore direct-to-manufacturer prescription contracting; the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC; and Seminole County, Florida posted an IFB (posted June 30, 2026, due July 26, 2023) for naloxone and safe drug deactivation systems with quarterly deliveries and a two-year initial term. The code shows recent activity in Florida, Texas, and Minnesota, though the lack of direct lonazolac calcium solicitations suggests pursuing this code carries execution risk unless your firm holds naloxone, pharmaceutical distribution, or cooperative-purchasing capabilities unrelated to the nominal code scope.